Finalist
Striving for Better Patient Outcomes in Psoriasis with Cosentyx (secukinumab)
Summary of work
In March 2018, patients and HCPs were ‘settling’ for sub-par psoriasis treatments that did not fully clear patients’ skin, despite such treatments being available. Visible, painful skin lesions profoundly affect patients’ lives, and incomplete treatment still leaves sufferers carrying this burden. In addition, co-morbid conditions related to psoriasis were often being treated by completely separate teams, leading to disjointed care and suboptimal outcomes.
Novartis aimed to change this, and help psoriasis patients achieve better quality of life through the right treatments and holistic care.
By June 2019, a wealth of educational content had been delivered to various audiences involved in the psoriasis patient journey, with the aim of informing the dermatology community how Cosentyx can offer superior outcomes and better quality of life to patients. Messaging emphasised benefits of treating the complete patient, treating early, and how optimal results can be obtained in biologic-naïve patients. Delegate feedback indicated that these messages were clearly understood, and that appropriate changes to clinical practice would be made.
Cosentyx was the original IL-17A inhibitor on the market and continues to thrive in a crowded market of competitors, including biosimilars, four years after launch.
Judges’ comments
Novartis and 90TEN’s project started with a stakeholder interview and it had a good range of measures. It was all about the profound impact on patients, the personas were good and there was good evidence of changing clinical practices.
